Knowledge about antipsychotic long-acting injections: bridging that gap

Knowledge about antipsychotic long-acting injections: bridging that gap

Bibliographic Details
Main Author:	Burns, T
Format:	Journal article
Published:	2009

Similar Items

Second Generation Long-Acting Injectable Antipsychotics in Africa: About a Case
by: J. Galvañ, et al.
Published: (2023-03-01)

Long acting injectable antipsychotics – Where are we?
by: Phani Prasant Mulakaluri
Published: (2015-01-01)

Prescribing practice of long-acting injectable antipsychotics
by: Jisha M Lucca, et al.
Published: (2020-01-01)

The Use of Long-Acting Injectable Antipsychotic Therapy for Schizophrenia
by: Jason Jiang, et al.
Published: (2018-09-01)

Long-acting injectable antipsychotics during pregnancy: An update
by: A. Paraschakis, et al.
Published: (2021-04-01)

The place of long-acting injectable antipsychotics in the treatment of schizophrenia
by: John M. Kane, et al.
Published: (2023-03-01)

Attitudes and perceptions about the use of long-acting injectable antipsychotics among behavioral health practitioners
by: Shaina Schwartz, PharmD, BCPP, et al.
Published: (2023-08-01)

Review of Pharmacokinetics and Pharmacogenetics in Atypical Long-Acting Injectable Antipsychotics
by: Francisco José Toja-Camba, et al.
Published: (2021-06-01)

The use of long-acting injectable antipsychotics in an acute psychiatric unit
by: G. Ortega-Hernández, et al.
Published: (2023-03-01)

Comparison of long-acting injectable antipsychotics with oral antipsychotics and hospital readmission rates in pediatric patients
by: Danial Chowdhury, PharmD, et al.
Published: (2024-04-01)

The evolution of antipsychotic medication: a long-acting injectable formulation of a second-generation antipsychotic
by: Piet Oosthuizen
Published: (2006-06-01)

Patient and Health Care Provider Perspectives on Long Acting Injectable Antipsychotics in Schizophrenia and the Introduction of Olanzapine Long-Acting Injection
by: Heidi J. Wehring, et al.
Published: (2011-06-01)

Positive views on antipsychotic long-acting injections: results of a survey of community patients prescribed antipsychotics
by: Shubhra Mace, et al.
Published: (2019-07-01)

Expert Consensus on Long-acting Injectable Antipsychotic in the Treatment of Schizophrenia in Community
by: Chinese Schizophrenia Coordination Group, Chinese Society of Psychiatry, Chinese Society of General Practice
Published: (2022-10-01)

Long-Acting Injectable Antipsychotics—A Review on Formulation and In Vitro Dissolution
by: Magdalena Markowicz-Piasecka, et al.
Published: (2023-12-01)

Analysis of Oral versus Long-acting Injectable Antipsychotics in the Maintenance of Schizophrenia
by: O. Vasiliu
Published: (2022-06-01)

Practical Guidance for the Use of Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia
by: Riboldi I, et al.
Published: (2022-12-01)

Rating Opportunity for Long-Acting Injectable Antipsychotic Initiation Index (ROLIN)
by: Petru Ifteni, et al.
Published: (2021-12-01)

Attitudes of European physicians towards the use of long-acting injectable antipsychotics
by: Maxine X. Patel, et al.
Published: (2020-03-01)

Patient perspectives in the development and use of long-acting antipsychotics in schizophrenia: focus on olanzapine long-acting injection
by: Leslie Citrome
Published: (2009-11-01)

Treatment effectiveness of shifting from risperidone long-acting injectable to first-generation long-acting injectable antipsychotics in patients with schizophrenia
by: Ching- Yin Chang, et al.
Published: (2019-01-01)

Effects of long-acting injectable antipsychotics versus oral antipsychotics on autonomic nervous system activity in schizophrenic patients
by: Suda A, et al.
Published: (2018-09-01)

Is paliperidone palmitate more effective than other long-acting injectable antipsychotics?
by: Patel, R, et al.
Published: (2017)

Effect of Transition to Long-acting Injectable Antipsychotic Treatment on Care Burden in Schizophrenia
by: Elif Özcan Tozoğlu, et al.
Published: (2021-12-01)

Assessment of oral overlap with antipsychotic long-acting injectables initiated in an inpatient setting
by: Tran Jennifer T. PharmD, et al.
Published: (2023-06-01)

The combination of long-acting injectable antipsychotics, a new key in resistant schizophrenia
by: M.F. Tascón Guerra, et al.
Published: (2022-06-01)

The Effect of Longer Dosing Intervals for Long-Acting Injectable Antipsychotics on Outcomes in Schizophrenia
by: Milz R, et al.
Published: (2023-03-01)

Long-acting injectable antipsychotics for early psychosis: A comprehensive systematic review.
by: Lulu Lian, et al.
Published: (2022-01-01)

Exercise and Worsening of Extrapyramidal Symptoms during Treatment with Long-Acting Injectable Antipsychotics
by: David D. Kim, et al.
Published: (2021-07-01)

Why we should use long-acting injectable antipsychotics more frequently
by: João Paulo Maia-de-Oliveira, et al.
Published: (2013-09-01)

Attitudes toward long-acting injectable antipsychotics among patients with schizophrenia in Japan
by: Sugawara N, et al.
Published: (2019-01-01)

Patients’ experiences of long-acting injectable antipsychotics: a qualitative study
by: Chiu LL, et al.
Published: (2019-07-01)

The modern perspective for long-acting injectables antipsychotics in the patient-centered care of schizophrenia
by: Pietrini F, et al.
Published: (2019-04-01)

Time to rehospitalization in involuntarily hospitalized individuals suffering from schizophrenia discharged on long-acting injectable antipsychotics or oral antipsychotics
by: Ching-Hua Lin, et al.
Published: (2022-03-01)

Long-Acting Injectable Antipsychotic Use in Patients with Schizophrenia and Criminal Justice System Encounters
by: Madhav P. Bhatta, et al.
Published: (2021-05-01)

Catatonia-related adverse outcomes after long-acting injectable antipsychotics: Case series
by: Joseph D Dragonetti, et al.
Published: (2024-01-01)

The effect of long-acting injectable antipsychotics on QRISK3 in patients with bipolar disorder and schizophrenia
by: V. Erbasan, et al.
Published: (2023-03-01)

Long-Acting Injectable Antipsychotic Treatment for Schizophrenia in Asian Population: A Scoping Review
by: Ma N, et al.
Published: (2023-09-01)

Use of Antipsychotic Long-acting Injection in Ekbom Syndrome: A Case of Delusional Parasitosis
by: Elvan ÇİÇEKÇİ, et al.
Published: (2020-07-01)

Metabolic Syndrome in Psychotic Disorder Patients Treated With Oral and Long-Acting Injected Antipsychotics
by: Antonio Ventriglio, et al.
Published: (2019-01-01)